Eli Lilly and Company reported second-quarter 2026 financial results on August 5, 2026, announcing a 48% year-over-year revenue increase to $23.0 billion, driven by strong volume growth in Mounjaro and Zepbound. Reported earnings per share rose 26% to $7.94, while non-GAAP EPS increased 33% to $8.38; both figures included significant acquired IPR&D charges of $3.03 per share related to recent acquisitions. The company raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion and updated non-GAAP EPS guidance to $35.50–$36.50, reflecting underlying growth offset by acquisition-related charges. Additionally, Lilly committed an additional $4.5 billion to expand manufacturing capacity in Indiana and highlighted regulatory approvals for Ebglyss and Jaypirca alongside positive Phase 3 data for retatrutide. Eli Lilly is a global pharmaceutical company focused on discovering, developing, and delivering medicines for diabetes, obesity, oncology, immunology, neuroscience, and other therapeutic areas.

Eli Lilly and Company has filed an 8-K to announce its financial results for the first quarter ended March 31, 2026. This disclosure is a critical event for investors as it provides the latest quarterly performance data necessary to assess the company's growth trajectory and financial health.

Eli Lilly and Company has released its financial results for the quarter and fiscal year ended December 31, 2025. This filing is a critical event for investors as it provides the official disclosure of the company's recent earnings and operational performance.

Eli Lilly and Company has released its financial results for the quarter ended September 30, 2025. This announcement provides the latest update on the company's operational performance and is a critical event for investors assessing the firm's growth trajectory and valuation.